B. Riley Securities Reiterates Buy on Journey Medical, Lowers Price Target to $13
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and lowers the price target from $15 to $13.
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and lowers the price target from $15 to $13.
